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Pulmonary hypertension 
Tony Glaus, Prof. Dr. med. Vet., Dipl. ACVIM and ECVIM-CA, Head Division of 
Cardiology, Vetsuisse Faculty University of Zurich, CH-8057 Zurich 
 
Definitions 
Pulmonary hypertension (PH) is defined as elevated pulmonary artery pressure (PAP) 
secondary to various pathophysiologies causing cor pulmonale and eventually right 
sided heart failure. The WHO classification of PH is based on similarities in 
pathophysiologic mechanisms (see table below). Specific hemodynamic criteria include 
systolic PAP >30 mmHg, diastolic PAP >20 mmHg, mean PAP >25 mmHg, pulmonary 
capillary wedge pressure <15 mmHg. 
Pulmonary arterial hypertension (PAH) is a progressive vasoproliferative condition 
characterized by increased pulmonary artery pressure. Patients with PAH by definition 
do not have significant left heart disease, lung disease or chronic thromboembolic 
disease. Idiopathic PAH (formerly primary PH or PPH) is diagnosed, when no 
underlying cause for PH and characteristic histological abnormalities in small 
pulmonary arteries  can be identified. Histological abnormalities include intimal, medial 
and adventitial proliferation, plexogenic changes consisting of proliferating epithelial 
cells mixed with myofibroblasts and necrotizing arteritis. 
Cor pulmonale refers to right ventricular hypertrophy secondary to PH. 
 
Etiology and pathophysiology 
In PAH, the underlying vascular injury is thought to be a final common response to 
various inciting factors coupled with genetic susceptibility. Eliciting factors may be 
mechanical (overperfusion), drugs (experimentally inducible with appetite 
suppressants), toxins, infections, and genetically determined susceptibility to such 
injuries. Thrombosis elicited by diseased vessel walls may complicate PAH. 
PH is a common complication of different cardiac and extracardiac diseases and 
results from two main mechanisms: increased left atrial pressure and increased 
pulmonary vascular resistance. Important causes are  
Cardiac: Pulmonary venous hypertension due to increased left atrial pressure in left 
myocardial failure, most common in advanced chronic mitral regurgitation, also in 
dilated cardiomyopathy; cor triatriatum sinister, mitral stenosis. 
Hypoxic vasoconstriction: Chronic obstructive lower airway disease (bronchitis, 
emphysema); chronic obstructive upper airway disease; high altitude hypoxia 
Occlusion of the pulmonary vascular bed: PTE; Parasites (D . immitis, A. vasorum), 
Pulmonary parenchymal disease: Pulmonary fibrosis; ARDS 
Combination of mechanisms, e.g., heartworm infection (D . immitis, A. vasorum): 
obstruction by intravascular parasites, vasculitis, thrombosis, and hypoxic 
vasoconstriction. 
 
Table: C lassification of pulmonary hypertension* 
 
G roup 1. Pulmonary arterial hypertension (PA H) 
Idiopathic (formerly primary PH, PPH) 
Associated with congenital systemic-to-pulmonic shunts 
Persistent pulmonary hypertension of the newborn 
Associated with drugs, toxins, inflammatory conditions 
 
G roup 2. Pulmonary hypertension associated with left heart disease 
Left ventricular or atrial disease 
Left-sided valvular disease 
 
G roup 3. Pulmonary hypertension associated with respiratory disease and/or 
hypoxemia 
Interstitial lung disease, e.g. pulmonary fibrosis 
Chronic upper airway obstruction 
Chronic exposure to high altitude 
 
G roup 4. Pulmonary hypertension due to thromboembolic disease 
Primary cardio-vascular lesion, e.g. D . immitis, A. vasorum 
Medical condition predisposing to pulmonary thromboembolism 
 
G roup 5. Miscellaneous 
 
*source: WHO classification, Chin and Rubin, 2008, modified and adapted for dog 
 
Diagnosis 
Thoracic radiographs for signs of PH as well as potential underlying cause of PH.  
Dorsoventral view particularly helpful to document right ventricular and main 
pulmonary artery enlargement. Peripheral pulmonary vasculature may be tortuous and 
enlarged. 
Left atrium is enlarged and pulmonary veins are congested with underlying left atrial, 
ventricular or mitral valve disease. 
Signs of underlying bronchial, interstitial or alveolar pulmonary disease may be evident. 
Echocardiogram, dual role: 
Rule in or out causes of PH, including acquired left ventricular heart disease (mitral 
endocardiosis, dilated cardiomyopathy) and congenital cardiovascular shunt. 
Confirmation of PH qualitatively and quantitatively: 
Qualitatively: characteristic two-dimensional and M-mode findings in moderate to 
severe PH are dilation of right ventricle and atrium, thickening of right ventricular wall 
and papillary muscles, paradoxical septal motion, and decreased left ventricular 
chamber size. 
Quantitatively: Doppler examination is the most useful noninvasive clinical tool to 
confirm and quantitate severity of PH. Systolic: velocity of tricuspid regurgitation (TR) 
correlates to right ventricular systolic pressure, and therefore, barring pulmonic stenosis, 
to pulmonary arterial systolic pressure. The modified Bernoulli equation allows Doppler-
derived blood flow velocities to be used for estimating intracardiac pressures: PG = 4 ?  
(Vmax)2, where PG is the peak pressure gradient between right ventricle and right atrium, 
in mmHg, and Vmax is the peak velocity of tricuspid regurgitation (TR), in m/sec. It is 
assumed that right atrial pressure approximates 0 mmHg during ventricular systole, such 
that the right atrial:right ventricular systolic PG equals systolic right ventricular pressure. 
A TR-PG >30 mmHg (Vmax >2.8 m/s) suggests/indicates systolic PH. Diastolic 
pulmonary artery pressure is calculated with Doppler quantification of pulmonary valve 
insufficiency (PI) instead of tricuspid regurgitation; by this method PH is considered to be 
present when PI-PG is >20 mmHg  (Vmax >2.2 m/s). 
 
Advanced or confirmatory testing 
Contrast ultrasound (microbubbles) of the heart and descending aorta to rule out 
cardiovascular right-to-left shunt. Shunt is also possible due to pulmonary arteriovenous 
fistula secondary to pulmonary hypertension; in this case, bubbles will take at least 3 
cardiac cycles from their appearance in the right atrium till their appearance in the left 
atrium. 
Right-sided cardiac catheterization for invasive measurement of pulmonary wedge 
pressure as an estimate of left atrial pressure, systolic and diastolic pulmonary artery 
pressure; evaluation of therapeutic intervention 
Pulmonary angiography; tortuous pulmonary arteries indicate PH, perfusion deficits are 
present in PTE 
Pulmonary Computed Tomography (CT) to identify / rule-out parenchymal disease and 
Angio-CT for PTE. 
Pulmonary ventilation-perfusion scintigraphy to rule out PTE 
Pulmonary histopathologic evaluation to confirm PAH 
 
Therapeutic goals 
PH of any genesis with signs referable to right ventricular forward or backward failure: 
lower pulmonary artery pressure 
PH of any genesis with signs referable to hypoxia: improve oxygenation 
PH with known pathogenesis and treatable cause: focus should be to correct/improve 
underlying disease 
There is no randomized trial documenting efficacy of medical treatment in naturally 
occurring PH in dogs; thus the following are merely treatment considerations: 
Therapeutic trial with amlodipine (Norvasc) in moderate PH, starting at 0.05 mg/kg PO 
q 24h and titrating dose based on response and BP (avoid hypotension) 
Anticoagulant therapy with low dose aspirin, 2?5 mg/kg PO q 12h (dog) 
Sildenafil (Viagra) in severe PH, 2?3 mg/kg PO q 8-12h. Improves clinical condition in 
the absence of significant effects on PAP as estimated by TR-PG. 
Oral L-Arginine, a precursor of nitric oxide, may be a simple and useful oral medical 
treatment, however, no studies documenting effect.  
Dedicated owner may consider intermittent oxygen therapy at home 
Pimobendan may lower PAP 
Furosemide, ACE inhibitor, spironolactone in case of overt right-sided congestive heart 
failure.  
Specific treatment of underlying mechanism or disease in secondary PH (Heart Failure, 
Pulmonary Thromboembolism, Dirofilariosis, Angiostrongylosis) 
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